

George R Bailie, MSc, PharmD, PhD

CURRICULUM VITAE

🔗 EDUCATION

- 1973-77 Bachelor of Science in Pharmacy, Queen's University of Belfast, Northern Ireland.
- 1977-78 Master of Science in Pharmacology, University of Strathclyde, Scotland.
- 1981-83 Doctor of Pharmacy, University of Minnesota.
- 1983-84 Post Doctoral Fellowship in Infectious Diseases, University of Minnesota.
- 1983-84 Research Fellow in Infectious Disease, University of Minnesota.
- 1987-92 Doctor of Philosophy (Clinical Pharmacy), University of Wales.

🔗 LICENSURE

New York State Board of Pharmacy, # I043285;

🔗 PROFESSIONAL EXPERIENCE

- 1979-80 Pharmacist (Grade 1), Southern General Hospital, Glasgow, UK.
- 1980-81 Pharmacist (Grade 2 Staff Pharmacist), Drug Information & Ward Pharmacy, Southern General Hospital, Glasgow, UK.
- 1984-88 Director of Pharmaceutical Services (Grade 5 Principal Pharmacist), Hope Hospital, Salford, and Lecturer in Hospital Pharmacy, University of Manchester, UK.
- 1987-90 Director, Meducate Ltd, Manchester, UK.
- 1988-91 Associate Professor of Pharmacy Practice, Albany College of Pharmacy, Albany, NY.
- 1991-2013 Professor of Pharmacy Practice, Albany College of Pharmacy, NY.
- 1996- Adjunct Professor of Medicine, Division of Nephrology, Albany Medical College, NY.
- 1997-07 Partner, Nephrology Pharmacy Associates, Inc., MI.
- 2007-2008 Associate Dean of Research & Graduate Education, Albany College of Pharmacy, NY.
- 2007- Partner, Renal Pharmacy Consultants LLC, Ann Arbor, MI
- 2013- Professor Emeritus, Albany College of Pharmacy & Health Sciences

🔗 PUBLICATIONS

A. Original Research

1. **Bailie GR**, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. *Kidney Int* 2015;87:162-8.
2. **Bailie GR**, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason NA, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant* 2013; 28: 2570-2579.

3. **Bailie GR**, Schuler C, Leggett RE, Li H, Li H-D, Patadia H, Levin R. Oxidative effect of several intravenous iron complexes in the rat. *Biometals* 2013;26:473-8. DOI: 10.1007/s10534-013-9632-4.
4. **Bailie GR**, Schuler C, Leggett RE, Levin R. Oxidative effect of ferumoxytol and iron dextran on urinary bladder contraction and impact of antioxidants. *Free Radicals Antioxidants* 2013;3:7-10. DOI: 10.1016/j.fra.2013.04.005.
5. Malone M, Alger-Mayer S, Lindstrom J, **Bailie GR**. Management of iron deficiency and anemia after Roux-en-Y gastric bypass surgery: an observational study. *Surgery for Obesity and Related Disorders* 2013 Feb 13. pii: S1550-7289(13)00039-7. doi: 10.1016/j.soard.2013.01.019.
6. **Bailie GR**, Verhoef JJ. Differences in serious allergic adverse events reporting rates from intravenous iron by country and by population. *Clin Adv Hematol Oncol* 2012;10:102-107.
7. **Bailie GR**. Comparison of serious adverse events from intravenous iron products in the United States. *Am J Health-Syst Pharm* 2012;69:310-320.
8. **Bailie GR**, Horl W, Verhoef J-J. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. *Arzneimittelforschung/Drug Research* 2011;61:267-75.
9. Cardone KE, Manley HJ, Grabe DW, Meola S, Hoy CD, **Bailie GR**. Quantifying home medication regimen changes and quality of life in patients receiving nocturnal home hemodialysis. *Hemodial Int* 2011;15:234-42.
10. **Bailie GR**, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. *Hemodial Int* 2010;14:47-54.
11. Ramirez SPB, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, Young EW, **Bailie GR**, Pisoni RL, Port FK. Rosiglitazone and mortality in chronic hemodialysis patients in the DOPPS. *J Am Soc Nephrol* 2009;20:1094-1101.
12. Bragg-Gresham JL, Fissell RB, Mason NA, **Bailie GR**, et al. Diuretic use, residual renal function and mortality among hemodialysis patients in DOPPS. *Am J Kidney Dis* 2007;49:426-431.
13. **Bailie GR**, Elder SJ, Mason NA, et al. Sexual Dysfunction in Dialysis Patients Treated with Antihypertensive or Antidepressive Medications: Results from the Dialysis Outcomes and Practice Patterns Study. *Nephrol Dial Transplant* 2007;22:1163-1170.
14. **Bailie GR**, Mason NA, Elder SJ, Andreucci VE, Greenwood RN, Akiba T, Saiyo A, Bragg-Gresham JL, Gillespie BW, Young EW. Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: The Dialysis Outcomes and Practice Patterns Study. *Hemodialysis Int* 2006;10:180-188.
15. Elwell RJ, Manley HJ, Frye RF, **Bailie GR**. Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. *Int J Artif Organs* 2006;28:808-816.
16. **Bailie GR**, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. *Nephrol Dial Transplant* 2005;20:1443-1449.

17. **Bailie GR**, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, Wolfe R, Port F, Burrows-Hudson S, Saran R. Patterns of medication use in the RRI-CKD Study: focus on medications with cardiovascular effects. *Nephrol Dial Transplant* 2005;20:1110-1115.
18. Elwell RJ, Frye RF, **Bailie GR**. Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis. *Perit Dial Int* 2005; 25: 380-386.
19. Charytan C, Qunibi W, **Bailie GR**, for the Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. *Nephron Clin Pract* 2005; 100: c55-c62.
20. **Bailie GR**, Mason NA, Elwell RJ, Sy FZ. Analysis of medication use in peritoneal dialysis patients in two units. *Perit Dial Int* 2005; 25:287-290.
21. Mason NA, **Bailie GR**, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, Combe C, Rayner HC, Saito A, Gillespie BW, Young EW. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. *Am J Kidney Dis* 2005, 45: 119-126.
22. Manley HJ, Elwell RJ, **Bailie GR**, Welch C. Intraperitoneal cefazolin and ceftazidime effects on human peritoneal mesothelial cell release of cancer antigen-125. *Ann Pharmacother* 2004, 38(12): 2035-2040.
23. **Bailie GR**, Mason NA, Bragg-Gresham JL, Gillespie BW, Young EW. Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription. *Kidney Int* 2004; 61: 2419-2425.
24. Perlman RL, Kiser M, Finkelstein F, Eisele G, Roys E, Liu L, Burrows-Hudson S, Port F, Messana J, **Bailie GR**, Rajagopalan S, Saran R. The longitudinal chronic kidney disease study: a prospective cohort study of predialysis renal failure. *Semin Dial* 2003; 16: 418-423.
25. Elwell RJ, Neumann M, **Bailie GR**. Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing hemodialysis: a retrospective cohort study. *Pharmacotherapy* 2003; 23: 1558-63.
26. Manley HJ, Bridwell DL, Elwell RJ, **Bailie GR**. Influence of peritoneal dialysate flow rate on the pharmacokinetics of cefazolin. *Perit Dial Int* 2003; 23: 469-474.
27. Elwell RJ, Neumann M, Manley HJ, Carpentier L, **Bailie GR**. Hepatitis B vaccination: addressing a drug-related problem in hemodialysis outpatients with a collaborative initiative. *Nephrol Nurs J* 2003; 30: 310-3.
28. Elwell RJ, Manley HJ, **Bailie GR**. Impact of introductory pharmacy experience on student learning, satisfaction and clerkship site productivity: assessment of the EPOC program. *Internat J Pharm Ed* 2003; 1: 10-18.
29. Manley HJ, **Bailie GR**, McClaran ML, Bender WL. Gentamicin pharmacokinetics during slow daily home hemodialysis. *Kidney Int* 2003; 63: 1072-8.
30. Elwell RJ, **Bailie GR**. Influence of classroom and clinical experience on the ethical decisions made by doctor of pharmacy students. *Intl J Pharm Educ* 2003; 1: 1-9.
31. Johnson CA, McCarthy J, **Bailie GR**, Deane J, Smith S. Analysis of renal bone disease management in dialysis patients in Network 11. *Am J Kidney Dis* 2002; 39:1270-1277.

32. Flanigan MJ, Frankenfield DL, Prowant BF, **Bailie GR**, Frederick PR, Rocco MV. Nutritional markers during peritoneal dialysis: data from the 1998 Peritoneal Dialysis Core Indicators Study. *Perit Dial Int* 2001; 21:345-354.
33. Mason NA, St. Peter WL, **Bailie GR**, Johnson CA. Clinical and practical perspectives on the use of intravenous vs. subcutaneous epoetin alfa in hemodialysis patients. *Dial Transplant* 2001; 30: 522, 524-526, 528, 546.
34. Manley HJ, **Bailie GR**, Frye RF, McGoldrick MD. Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. *Perit Dial Int* 2001; 21: 378-385.
35. Manley HJ, **Bailie GR**. Effects of intraperitoneal cefazolin on mesothelial cells in non-infected CAPD patients. *Perit Dial Int* 2001; 21: 83-85.
36. Sowinski KM, Mueller BA, Grabe DW, Manley HJ, Frye RF, **Bailie GR**, Marx MA. Cefazolin dialytic clearance by high efficiency and high flux dialyzers. *Am J Kidney Dis* 2001; 37: 766-776.
37. Manley HJ, **Bailie GR**, Frye R, McGoldrick MD. Pharmacokinetics of intermittent intravenous piperacillin in patients treated with automated peritoneal dialysis. *Perit Dial Int* 2000; 20: 686-693.
38. Elwell R, Manley HJ, **Bailie GR**. Correlation of intraperitoneal antibiotic pharmacokinetics with peritoneal membrane transport characteristics. *Perit Dial Int* 2000; 20: 694-698.
39. Manley HJ, **Bailie GR**, Neumann M. Antibigram development for an outpatient dialysis center. *Am J Health-Sys Pharm* 2000; 35: 251-3.
40. Manley HJ, **Bailie GR**, Grabe DW. National database information: utility for an individual dialysis center. *Am J Health-Sys Pharm* 2000; 57: 902-6.
41. Manley HJ, **Bailie GR**, Frye RF, Hess LD, McGoldrick MD. Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in automated PD patients. *J Am Soc Nephrol* 2000; 11: 1310-1316.
42. Flanigan MJ, Rocco MV, Frankenfield D, **Bailie GR**, Frederick P, Prowant B, Taylor L. 1997 Peritoneal Dialysis Core Indicators Study: dialysis adequacy and nutritional indicators report. *Am J Kidney Dis* 1999; 33: E3. [electronic pages - www.ajkdjournal.org].
43. Manley HJ, Grabe DW, Norcross M, Stinchcomb AL, Hass M, **Bailie GR**. Stability of amphotericin B lipid complex (Abelcet) in PD solutions. *Perit Dial Int* 2000; 20: 87-90.
44. Possidente CJ, **Bailie GR**, Hood VL. Pharmacist identification and resolution of drug-related problems in chronic dialysis patients during hospitalization. *Am J Health-Sys Pharm* 1999; 56: 1961-1964.
45. Mason NA, St. Peter WM, Johnson CA, **Bailie GR**. The Clinical Pharmacy Dialysis Traineeship: a survey of the trainees' activities and experiences. *Am J Health-Sys Pharm* 1999; 56: 1623-1626.
46. Manley HJ, Grabe DW, **Bailie GR**, Norcross ML. Stability of iron dextran (DexFerrum®) in peritoneal dialysis bags. *Perit Dial Int* 1998, 18, 538-540.
47. Flanigan MJ, **Bailie GR**, Frankenfield DL, Frederick PR, Prowant BF, Rocco MV. 1996 peritoneal dialysis core indicators study: report on nutritional indicators. *Perit Dial Int* 1998, 18, 489-496.

48. Manley HJ, **Bailie GR**, Asher RD, Eisele G, Frye RF. Pharmacokinetics of intermittent intraperitoneal cefazolin in CAPD patients. *Perit Dial Int* 1999; 19: 65-70.
49. **Bailie GR**, Frankenfield DL, Prowant BF, McClellan W, Rocco MV. Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA End-Stage Renal Disease Core Indicators Project. *Am J Kidney Dis* 1999, 33: 1187-1189.
50. Frankenfield DL, Prowant BF, Flanigan MJ, Frederick PR, **Bailie GR**, Helgeson SD, Rocco MV. Trends in clinical indicators of care for adult peritoneal dialysis patients in the US, 1995-1997. *Kidney Int* 1999; 55: 1998-2010.
51. Grabe DW, **Bailie GR**, Eisele G, Frye RF. Pharmacokinetics of intermittent intraperitoneal ceftazidime in CAPD patients. *Am J Kidney Dis* 1999; 33: 111-117.
52. Flanigan MJ, Rocco MV, Frankenfield DL, **Bailie GR**, Frederick PR, Prowant BF, Taylor L. 1996 Peritoneal Dialysis: Core Indicators Report. *Am J Kidney Dis* 1998; 32: E3. [electronic pages - www.ajkdjournal.org].
53. Grabe DW, **Bailie GR**, Manley JH, Yeaw BF. The Early Patient-Oriented Care (EPOC) program as an educational tool and service. *Am J Pharm Ed* 1998; 62; 278-284.
54. Grabe DW, **Bailie GR**, Eisele G, Low CL. Hemodialysis patients' knowledge of their phosphate binder therapy. *J Applied Ther Res* 1999; 2: 125-132.
55. Snitkoff GG, Grabe DW, Holt R, **Bailie GR**. Development of an immunoassay for monitoring the levels of ciprofloxacin in patient samples. *J Immunoassay* 1998; 19; 227-238.
56. Lau AH, **Bailie GR**, Matzke GR. The practice of nephrology pharmacy: results of a North American survey. *J Appl Ther Res* 1999; 2: 91-100.
57. Mathai L, **Bailie GR**, Eisele G. Assessment of hemodialysis patients' knowledge regarding calcitriol therapy. *J Appl Ther* 1998; 1: 295-303.
58. **Bailie GR**, Low CL, Eisele G. Erythropoietin effectiveness index: a quantitative definition of resistance in hemodialysis patients with adequate iron stores. *Clin Drug Invest* 1998; 15: 57-60.
59. Low CL, **Bailie GR**, Eisele G. Sensitivity and specificity of transferrin saturation as markers of iron status after intravenous iron dextran in hemodialysis patients. *Renal Fail* 1997; 19: 781-788.
60. **Bailie GR**, Handa JJ, Tang L, Low CL, Eisele G. Minimal removal of iron-dextran by conventional hemodialysis: an *in vivo* study. *Clin Drug Invest* 1997; 14: 12-15.
61. Grabe DW, Low CL, **Bailie GR**, Eisele G. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. *Clin Nephrol* 1997; 47: 117-121.
62. Malone M, **Bailie GR**, Eisele G. The effect of recombinant human erythropoietin on the quality of life of CAPD patients. *J Applied Ther* 1996; 1: 39-43.
63. Low CL, **Bailie GR**, Evans A, Eisele G, Venezia RA. Pharmacokinetics of once-daily ip gentamicin in CAPD patients. *Perit Dial Int* 1996; 16: 379-384.
64. Low CL, **Bailie GR**, Rasmussen R, Eisele G. Variability in weekly Clcr and KT/V due to different methods of calculation. *Perit Dial Int* 1996; 16: 366-369. (see associated editorial)

65. **Bailie GR**, Eisele G, Sala J, Wu D. Determination of iodixanol hemodialysis clearance using a novel *in vitro* system. *Clin Res Reg Aff* 1996; 13: 111-124.
66. Low CL, **Bailie GR**, Morgan S, Eisele G. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients. *Clin Nephrol* 1996; 45: 120-124.
67. **Bailie GR**, Romeo B. Internists' and family practitioners' attitudes to community pharmacists' clinical services. *Arch Intern Med* 1996; 156: 1437-1441.
68. Preston SL, Briceland LL, Lomaestro BM, Lesar TS, **Bailie GR**, Drusano GL. Dosing adjustment of 10 antimicrobials for patients with renal impairment. *Ann Pharmacother* 1995; 29: 1202-1207.
69. **Bailie GR**, Haqqie SS, Eisele G, Gorman T, Low CL. Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis. *Perit Dial Int* 1995; 15: 269-271. (see associated editorial, *ibid*, 201-202).
70. Battista C, Kane MP, Moon DG, **Bailie GR**. Stability of ofloxacin in peritoneal dialysis solutions. *Perit Dial Int* 1995; 15: 72-74.
71. Veivia AJ, **Bailie GR**, Eisele G. Knowledge of hemodialysis patients about erythropoietin and iron therapy. *Dial Transplant* 1995; 24: 21-30.
72. Kane MP, **Bailie GR**, Moon DG, Siu I. Stability of deferroxamine in peritoneal dialysis solutions. *Perit Dial Int* 1994; 14: 396-398.
73. Alexander ACM, Kane MP, **Bailie GR**. Incidence and risk factors of nephrotoxicity associated with intravenous immune globulin administration. *Hosp Pharm* 1994; 29: 449-450, 453-454, 457-458.
74. Wharton JA, **Bailie GR**. Simplified approach to calculation of V, G and nPCR for monitoring hemodialysis patients. *Renal Fail* 1994; 16: 285-293.
75. Kane MP, **Bailie GR**, Moon DG, Siu I. Stability of ciprofloxacin injection in peritoneal dialysis solutions. *Am J Hosp Pharm* 1994; 51: 373-377.
76. Kane MP, **Bailie GR**, Siu I, Moon DG, Eisele G. Stability of intravenous erythromycin lactobionate in peritoneal dialysate. *Perit Dial Int* 1994; 14: 79-81.
77. Lomaestro BM, **Bailie GR**. Effect of multiple doses of calcium on the bioavailability of ciprofloxacin. *Ann Pharmacother* 1993; 11: 1325-1328.
78. Alexander A, **Bailie GR**, Eisele G. Assessment of heparin use in the outpatient hemodialysis population. *NY State J Pharm* 1993; 13: 16-19.
79. Gailey R, **Bailie GR**. Gram staining of peritoneal dialysis effluent in peritonitis. *NY State J Pharm* 1993; 13: 14-15.
80. Lomaestro BM, **Bailie GR**, Eisele G. Timeliness of medication administration in hemodialysis inpatients. *Hosp Pharm* 1993; 28: 980-984.

81. **Bailie GR**, Rasmussen R, Eisele G, Luscombe DK. Peritonitis rates in CAPD patients using the UVXD and O-set systems. *Renal Fail* 1993; 15: 225-230.
82. Kowalsky SF, Echols RM, Schwartz MT, **Bailie GR**, McCormick EA. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. *Clin Nephrol* 1993; 39: 53-58.
83. Figge HL, **Bailie GR**, Briceland LL, Kowalsky SF. Possible guanciclovir-induced hepatotoxicity in patients with AIDS. *Clin Pharm* 1992; 11: 432-434.
84. Eisele G, **Bailie GR**, Lomaestro B. Relationship between peritonitis and exit site infections in CAPD. *Adv Perit Dial* 1992; 8: 227-229.
85. **Bailie GR**, Eisele G, Venezia RA, Yocum D, Hollister A. Prediction of serum vancomycin concentrations following intraperitoneal loading doses in CAPD patients with peritonitis. *Clin Pharmacokinet* 1992; 22: 298-307.
86. Eisele G, **Bailie GR**, Clement C, Wong E. Erythropoietin in CAPD patients: experience with subcutaneous administration. *Perit Dial Int* 1992; 12: 34-36.
87. **Bailie GR**, Cockshott ID, Douglas EJ. The pharmacokinetics of propofol during and following long term continuous infusion for maintenance of sedation in ICU patients. *Br J Anaesthesia* 1992; 68: 486-491.
88. **Bailie GR**, Hamilton R, Eisele G. Evaluation of an erythropoietin dosing nomogram in CAPD patients. *Int J Pharm Pract* 1992; 1: 164-166.
89. Briceland L, **Bailie GR**. Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. *DICP Ann Pharmacother* 1991; 25: 1171-1174.
90. **Bailie GR**, Plitnick R, Eisele G, Clement C, Rasmussen R. Experience with subcutaneous erythropoietin in CAPD patients. *Adv Perit Dial* 1991; 7: 292-295.
91. Lomaestro B, **Bailie GR**. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. *Antimicrob Agents Chemother* 1991; 35: 1004-1007.
92. Malone M, Hemingway J, Wiffen P, **Bailie GR**. Renal transplant patients' knowledge concerning cyclosporin treatment. *Clin Nephrol* 1991; 35: 88-89.
93. **Bailie GR**, Eisele G, Venezia RA, Litynski J, Hughes H. Recovery of *S. epidermidis* and *E. coli* from spent peritoneal dialysate. *Perit Dial Int* 1991; 11: 69-71.
94. **Bailie GR**, Kowalsky SF, Eisele G, Schwartzman MS. Disposal of CAPD waste in the community. *Perit Dial Int* 1991; 11: 72-75.
95. Blanchard R, Berger W, **Bailie GR**, Eisele G. Knowledge of hemodialysis and CAPD patients about their prescribed medicines. *Clin Nephrol* 1990; 34, 173-178.
96. **Bailie GR**, Rasmussen R, Hollister A, Eisele G. Incidence of CAPD peritonitis in patients using UVXD or O-set systems. *Clin Nephrol* 1990; 33: 252-254.
97. Nelson MV, **Bailie GR**, Areny H. Pharmacists' perceptions of alternative health approaches: a comparison of US and British pharmacists. *J Clin Pharm Ther* 1990; 15: 141-146.

98. Neal D, **Bailie GR**. Clearance from dialysate and equilibration of intraperitoneal vancomycin in CAPD. *Clin Pharmacokinet* 1990; 18: 485-490.
99. Nelson MV, **Bailie GR**. A survey of pharmacists' recommendations for food supplements in the USA and UK. *J Clin Pharm Ther* 1990; 15: 131-140.
100. Horsley MG, **Bailie GR**. Effectiveness of theophylline monitoring by the use of serum assays. *J Clin Pharm Ther* 1988; 13: 359-364.
101. Grennan A, **Bailie GR**, Weinkove C. Bumetanide assay using solid phase extraction. *J Drug Devel* 1988; 1: 105-108.
102. Kay EA, **Bailie GR**, Bernstein A. Patient knowledge of cardiorespiratory drugs. *J Clin Pharm Ther* 1988; 13: 263- 268.
103. **Bailie GR**, Kay EA. Patients' knowledge of sublingual glyceryl trinitrate. *Br Med J* 1988; 297: 32.
104. Horsley MG, **Bailie GR**. Risk factors for inadequate use of pressurised aerosol inhalers. *J Clin Pharm Ther* 1988; 13: 139-143.
105. **Bailie GR**, Waldek S. Pharmacokinetics of flecainide in a patient undergoing CAPD. *J Clin Pharm Ther* 1988; 13: 121- 124.
106. **Bailie GR**, Mathews A. Quantitative and qualitative assessment of serum concentration monitoring and dosage adjustment of aminoglycosides. *Ther Drug Monit* 1988; 10: 292-295.
107. Malone M, **Bailie GR**. User acceptability of six 3-litre total parenteral nutrition bags. *Intens Ther Clin Monit* 1988; 9: 95-97.
108. **Bailie GR**, Mathews A. Cost/benefit analysis of aminoglycoside use without a pharmacokinetic dosing service. *Drug Intell Clin Pharm* 1988; 22: 80-81.
109. Kay EA, **Bailie GR**. Educating patients about sublingual glyceryl trinitrate. *Pharm J* 1987; 239 (Suppl): R3.
110. **Bailie GR**, Mathews A. Is aminoglycoside - associated nephrotoxicity uncommon in the UK? *J Clin Pharm Ther* 1987; 12: 389-392.
111. **Bailie GR**, Bennett S. The development of patient-specific drug information leaflets. *Pharm J* 1987; 238: 803-804.
112. Rowland M, **Bailie GR**, Clark CM, et al. Manchester accreditation scheme for clinical pharmacy training. A report from the Committee on Studies in Clinical Pharmacy, University of Manchester. *Pharm J* 1987; 238: 588-589.
113. **Bailie GR**. Morton R, Ganguli L, Keaney M, Waldek S. Intravenous or intraperitoneal vancomycin for the treatment of CAPD-associated gram positive peritonitis? *Nephron* 1987; 46: 316-318.
114. McMahon T, Clark CM, **Bailie GR**. Who provides patients with drug information? *Br Med J* 1987; 294: 355-356.

- 115. Bailie GR**, Waldek S. Bioavailability of bumetanide in grossly oedematous patients. *Clin Pharmacokinet* 1987; 12: 440-443.
- 116. Kibirige MS**, Price DA, Shalet SM, **Bailie GR**. Plasma growth hormone (GH) responses to growth hormone releasing factor (hp GRF 1-44) in familial GH deficiency. *Acta Paediatr Scand* 1987; 76: 103-106.
- 117. Duckworth M**, **Bailie GR**. Evaluation of the efficacy of a computer generated dosage guide for intravenous infusions administered by infusion pump. *Pharm J* 1986; 237: 769.
- 118. Clark CM**, Whittacker A, **Bailie GR**, Goldberg LA. Parenteral drug delivery - value for money? *Pharm J* 1986; 236: 453-455.
- 119. Bailie GR**, Taylor RJ, Horsley MG. Syringe pump infusion rate program. *Pharm J* 1986; 236: 227.
- 120. Bailie GR**, Angaran DM. Evaluation of the appropriateness of use and outcome of serum digoxin assays. *Pharm J* 1986; 236: 392-393.
- 121. Bailie GR**. Structured pre-registration training. *Pharm J* 1986; 236: 151-152.
- 122. Bailie GR**, Kay EA, Taylor RJ. Computerised infusion rate chart. *Pharm J* 1985; 235: 684.
- 123. Bailie GR**, Ackerman BH, Fischer J, Solem LD, Rotschafer JC. Increased vancomycin dosage requirements in young burn patients. *J Burn Care Rehab* 1984; 5: 376-378.
- 124. Malcolm AD**, et al. Rhythmolan Multicentre Study Group. Oral disopyramide after readmission to hospital with suspected acute myocardial infarction. *Postgrad Med J* 1984; 60: 98-107.
- 125. Bailie GR**, Campbell ME, Kesson CM. Drug administration audit. *J Clin Hosp Pharm* 1981; 6: 285-286.
- 126. Bailie GR**, Calder IT, Kesson CM, Lawson DH. A comparison of temazepam with nitrazepam and with placebo as a hypnotic in medical patients in hospital. *J Clin Hosp Pharm* 1980; 5: 311-317.
- 127. Bailie GR**. Clinical trial to compare the hypnotic effects of temazepam, nitrazepam and placebo. *Proc Guild Hosp Pharm* 1980; (8): 56-61.

B. Reviews

1. **Bailie GR**. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. *ArzneimForsch/DrugRes* 2010, 60: 386-98.
2. Dominelli A, Iwanowicz SL, **Bailie GR**, Clarke DW, McGraw PS. A project management approach to an ACPE accreditation self-study. *Am J Pharmaceut Educ* 2007, 71: Article 23, 1-5.
3. Van Wyck DB, Eckardt K-U, Adamson JW, **Bailie GR**, et al. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. *Am J Kidney Dis* 2006, 47 (Suppl 3): S1-S146.
4. Cavill I, Auerbach M, **Bailie GR**, Barrett-Lee P, Beguine Y, Kaltwasser P, Littlewood T, Macdougall IC, Wilson K. Iron and the anaemia of chronic disease: a review and strategic recommendations. *Curr Med*

Res Opin 2006, 22: 731-737.

5. **Bailie GR**, Massry SG. Clinical practice guidelines for bone metabolism and chronic kidney disease: an overview. *Pharmacotherapy* 2005; 12: 1687-1707.
6. Manley HJ, Canella CA, **Bailie GR**, St. Peter WL. Medication-related problems in hemodialysis patients: a pooled analysis. *Am J Kidney Dis* 2005; 46: 669-680.
7. **Bailie GR**. Risk of allergic reactions: is there any reason to choose iron sucrose over iron dextran? Anemia Network Update 2005; 4: 4-6.
8. **Bailie GR**. Therapeutic dilemmas in the management of peritonitis. *Perit Dial Int* 2005; 25: 152-156.
9. Piraino B, **Bailie GR**, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. *Perit Dial Int* 2005; 25: 107-131.
10. **Bailie GR**, Uhlig K, Levey AS. Clinical Practice Guidelines in Nephrology: Evaluation, Classification and Stratification of Chronic Kidney Disease. *Pharmacotherapy* 2005; 25: 491-502.
11. **Bailie GR**. The role of intravenous iron in anemia management. *Pharm Pract News* July 2004; 47-51.
12. **Bailie GR**. Calcium and phosphorus management in chronic kidney disease: challenges and trends. *Formulary* 2004; 39: 358-362, 364-365.
13. Levey AS, **Bailie GR**, et al. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. *Am J Kidney Dis* 2004; 43 (Suppl 1): S1-S290.
14. **Bailie GR**. From DOQI to K/DOQI: new clinical practice guidelines in nephrology – what the practicing pharmacist needs to know. *Pharmacotherapy* 2004; 24: 551-557.
15. Manley HJ, **Bailie GR**. Treatment of peritonitis in automated peritoneal dialysis: pharmacokinetic principles. *Semin Dial* 2002; 15: 418-421.
16. **Bailie GR**, Johnson CA. Comparative review of the pharmacokinetics of vitamin D analogues. *Semin Dial* 2002; 15: 352-357.
17. Van Wyck DB, **Bailie GR**, Aronoff G. Just the FAQs: Frequently asked questions about iron and anemia in patients with chronic kidney disease. *Am J Kidney Dis* 2002; 39: 426-432.
18. Diaz-Buxo JA, Crawford TL, **Bailie GR**. Peritonitis in automated peritoneal dialysis: antibiotic therapy and pharmacokinetics. *Perit Dial Int* 2001; 21 (Suppl 3): S197-S201.
19. Keane WF, **Bailie GR**, Boeschoten E, et al. Adult peritoneal dialysis related peritonitis treatment recommendations. Update 2000. *Perit Dial Int* 2000; 20: 396-411. See also Diaz-Buxo JA, **Bailie GR**. Empiric initial therapy and dose of vancomycin. *Perit Dial Int* 2000; 20: 829 (letter). <http://www.ispd.org/guidelines/articles/update/ISPDperitonitis.php3>.
20. **Bailie GR**, Johnson CA, Mason NA. Iron dextran, iron sucrose and iron gluconate: parenteral iron use in the management of anemia in ESRD. *Formulary* 2000; 35: 498-513.
21. **Bailie GR**, Johnson CA, Mason NA. A review of parenteral iron preparations in ESRD: iron dextran, saccharate and gluconate. *Am J Kidney Dis* 2000; 35: 1-12.

22. Johnson CA, Mason NA, **Bailie GR**. Intravenous iron products. *ANNA J* 1999; 26: 522-524.
23. McGoldrick MD, **Bailie GR**. Non-narcotic analgesics: prevalence and estimated economic impact of toxicities. *Ann Pharmacother* 1997; 31: 221-227. (see associated editorial).
24. Keane WF, Alexander SR, **Bailie GR**, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Huang C-C, Kawaguchi Y, Piraino B, Riella M, Vas S. The Ad Hoc Advisory Committee on Peritonitis Management. Peritoneal dialysis related treatment recommendations: 1996 update. *Perit Dial Int* 1996; 16: 557-573.
25. **Bailie GR**, Eisele G. Vancomycin in PD-associated peritonitis. *Semin Dial* 1996; 9: 417-423.
26. **Bailie GR**, Kane MP. Stability of drug additives in peritoneal dialysate. *Perit Dial Int* 1995; 15: 328-335.
27. Lomaestro BM, **Bailie GR**. Absorption interactions with fluoroquinolones: 1995 update. *Drug Safety* 1995; 12: 314-333.
28. **Bailie GR**, Eisele G. Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. *J Antimicrob Chemother* 1995; 35: 563-567 (leading article).
29. **Bailie GR**. Clinical pharmacy care in CAPD. *J Pharm Pract* 1993; 6: 123-132.
30. **Bailie GR**, Eisele G. CAPD: a review of its mechanics, advantages, complications and areas of controversy. *Ann Pharmacother* 1992; 26: 1409-1420.
31. Lomaestro BM, **Bailie GR**. Quinolone-cation interactions: a review. *DICP Ann Pharmacother* 1991; 25: 1249-1258.
32. **Bailie GR**, Neal D. Vancomycin ototoxicity and nephrotoxicity: a review. *Med Toxicol* 1988; 3: 376-386.
33. **Bailie GR**. CAPD: The use of antibiotics in peritonitis. *Current Views* 1987; 2: 5-7.
34. Mathews A, **Bailie GR**. Clinical pharmacokinetics, toxicity and cost-effectiveness analysis of aminoglycosides and aminoglycoside dosing services - a review. *J Clin Pharm Ther* 1987; 12: 273-291.

C. Additional Articles

Chapters in Textbooks, Letters to the Editor; Published Abstracts, etc
Available on request.